US 2024/0189414 A1 · ENGINEERED HEARTLAND VIRUS MRNA VACCINE

Abstract

Provided herein are a Heartland virus vaccine composition including a messenger ribonucleic acid (mRNA) including an open reading frame (ORF) encoding Gn or Gc of Heartland virus, a Heartland virus vaccine composition comprising a messenger ribonucleic acid (mRNA) comprising an open reading frame (ORF) encoding Gn or Gc of Heartland virus fused with human collagen type I alpha 1 (COL1A1) signal peptide, and a method of inducing immune response against Heartland virus by administering an effective amount of the Heartland virus vaccine composition to a subject in need thereof.

Claims28

Dependent claims

A Heartland virus vaccine composition comprising

a messenger ribonucleic acid (mRNA) comprising an open reading frame (ORF) encoding Gn or Gc of Heartland virus, or the Gn or Gc of Heartland virus fused with human collagen type I alpha 1 (COL1A1) signal peptide.

Dependencies are inferred from the claim text.

Facts

Application

18/530,861Filed 6 Dec 2023

Priority

13 Dec 2022

Published

13 Jun 2024

Term ends

Not estimatedThe source records don’t support an estimate.

Classification11 codes

A61K 39/12
Medicinal preparations containing antigens or antibodies: viral antigens
C07K 14/005
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof: from viruses
A61K 9/5123
Excipients; Inactive ingredients: organic compounds, e.g. fats, sugars
C12N 7/00
Viruses

Engineered heartland virus mrna vaccine

Life of this patent

Engineered heartland virus mrna vaccine

Life of this patent

Abstract

Claims28